1-2 of 2
Mary Ann Melnick
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with EGFR-Mutant NSCLC (SWOG S1403)

Philip C. Mack, Jieling Miao, Mary W. Redman, James Moon, Sarah B. Goldberg, Roy S. Herbst, Mary Ann Melnick, Zenta Walther, Fred R. Hirsch, Katerina Politi, Karen Kelly, David R. Gandara
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3752–3760.
https://doi.org/10.1158/1078-0432.CCR-22-0741
Published: 01 September 2022
View article titled, Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with <em>EGFR</em>-Mutant NSCLC (SWOG S1403)
Open the PDF for Circulating Tumor DNA Kinetics Predict Progression-Free and Overall Survival in EGFR TKI–Treated Patients with <em>EGFR</em>-Mutant NSCLC (SWOG S1403) in another window
Includes: Supplementary data
Journal Articles

Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer

Ken Takezawa, Mary Ann Melnick, Greg Riely, Mark Kris, Vincent Miller, Marc Ladanyi, Katerina Politi, William Pao, Valentina Pirazzoli, Xiaoling Song, Maria Arcila, Elisa De Stanchina, Kadoaki Ohashi, Yelena Janjigian, Paula Spitzler, Caroline Nebhan
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (10_Supplement): A23.
https://doi.org/10.1158/1078-0432.MECHRES-A23
Published: 04 March 2013
View article titled, Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer
Open the PDF for Abstract A23: HER2 levels affect sensitivity and resistance to EGFR inhibition in EGFR mutant lung cancer in another window